In vitro and in vivo growth of B16F10 melanoma cells transfected with interleukin-4 cDNA and gene therapy with the transfectant

Blankenstein T, Qin Z, Überla K, Müller W, Rosen H, Volk H-D, Diamantstein T (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor ? gene transfer. J Exp Med 173:1047?1052

Bruggen PVD, Traversari C, Chomez P, Lurquin C, Plaen ED, Eynde BVD, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643?1647

Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G (1991) Granulocyte colony-stimulating factor gene transfer suppresses tumorigencity of a murine adenocarcinoma. J Exp Med 173:889?897

Crawford RM, Finbloom DS, Ohara J, Paul WE, Meltzer MS (1987) B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens. J Immunol 139:135?141

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll DM, Mulligan RC (1993) Vaccination with irradiated with tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539?3543

Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cell bypasses T helper function in the generation of an antitumor response. Cell 60:397?403

Felgner PL, Gadek TR, Holn M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M, (1987) Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84:7413?7417

Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990a) Retroviral vector-mediated ?-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50:7820?7825

Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990b) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217?1224

Golumbek PT, Lazenby AJ, Levitszky HI, Jaaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713?716

Hock H, Dorsch M, Diamantstein T, Blankenstein T (1991) Interleukin 7 induces CD4+ T cell-dependent and tumor rejection. J Exp Med 174:1291?1298

Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Homaoka T, Paul WE (1982) Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 155:914?923

Karasuyama H, Melchers F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18:97?104

Lutzker S, Rothman P, Pollock R, Coffman R, Alt FW (1988) Mitogen-and IL-4-regulated expression of germ-line Ig ?2b transcripts: evidence for directed heavy chain class switching. Cell 53:177?184

Mizuno M, Yoshida J, Sugita K, Inoue I, Seo H, Hayashi Y, Koshizaka T, Yagi K (1990) Growth inhibition of glioma cells transfected with the human ?-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res 50:7826?7829

Mosmann TR, Bond MW, Coffman RL, Ohara J, Paul WE (1986) T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci USA 83:5654?5658

Mulé JJ, Smith CA, Rosenberg SA (1987) Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 166:792?797

Noelle R, Krammer PH, Ohara J, Uhr JW, Vitetta ES (1984) Increased expression of Ia antigens on resting B cells: An additional role for B-cell growth factor. Proc Natl Acad Sci USA 81:6149?6153

Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Ohira T, Miura K, Nishio K Saijo N (1993a) Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 53:432?437

Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Saito H, Koishihara Y, Ohsugi Y, Ohira T, Saijo N (1993b) Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumor growth rate but cause weight loss and shorten survival in syngenic mice. Br J Cancer 67:939?944

Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L (1993) Anti-metastic vaccination of tumorbearing mice with IL-2-gene-inserted tumor cells. Int J Cancer 53:471?477

Roehm NW, Leibson HJ, Zlothik A, Kappler J, Marrack P, Cambier JC (1984) Interleukin-induced increase in Ia expression by normal mouse B cells. J Exp Med 160:679?694

Snapper CM, Paul WE (1987) B cell stimulatory factor-1 (interleukin 4) prepares resting murine B cells to secrete IgG1 upon subsequent stimulation with bacterial lipolysaccharide. J Immunol 139:10?17

Sun WH, Kresle RA, Phillips AW, Ershler WB (1992) In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res 52:5412?5415

Teng MN, Park BH, Koeppen HKW, Tracey KJ, Fendly BM, Schreiber H (1991) Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T cell immunity. Proc Natl Acad Sci USA 88:3535?3539

Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503?512

Watanabe Y, Kuribayashi K, Miyake S, Nishihara K, Nakayama E, Taniyama T, Sakata T (1989) Exogenous expression of mouse interferon ? cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 86:9456?9460

Widmer MB, Grabstein KH (1987) Regulation of cytolytic T-lymphocyte generation by B-cell stimulatory factor. Nature 326:795?798